1. Home
  2. ONEG vs SPRO Comparison

ONEG vs SPRO Comparison

Compare ONEG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneConstruction Group Limited Ordinary Shares

ONEG

OneConstruction Group Limited Ordinary Shares

HOLD

Current Price

$1.21

Market Cap

156.2M

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.26

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONEG
SPRO
Founded
2021
2013
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.2M
136.7M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
ONEG
SPRO
Price
$1.21
$2.26
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
564.2K
433.6K
Earning Date
08-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.08
N/A
Revenue
$53,205,000.00
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.51
52 Week High
$13.50
$3.22

Technical Indicators

Market Signals
Indicator
ONEG
SPRO
Relative Strength Index (RSI) 17.35 45.55
Support Level $1.07 $2.18
Resistance Level $1.95 $2.33
Average True Range (ATR) 0.31 0.11
MACD 0.10 -0.02
Stochastic Oscillator 12.98 20.51

Price Performance

Historical Comparison
ONEG
SPRO

About ONEG OneConstruction Group Limited Ordinary Shares

OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: